Physician profile
Charles Mathis
NPI 1033115274
$920.81
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $117 · 2022: $464 · 2023: $287 · 2024: $52.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $339.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $323.67 | 2022-2023 | Grafix Pl, Collagenase Santyl, Renasys Go V2 Home |
| Paratek Pharmaceuticals, INC. | $162.54 | 2022-2023 | Nuzyra |
| Abbvie INC. | $74.85 | 2022-2024 | |
| Intuitive Surgical, INC. | $65.82 | 2019 | |
| Davol INC. | $51.02 | 2019 | |
| Convatec INC. | $42.95 | 2022 | |
| Medtronic, INC. | $40.24 | 2022-2023 | Venaseal |
| Kci USA, INC. | $32.59 | 2022-2023 | Activ.A.C. |
| Abbott Laboratories | $30.17 | 2024 | Cardiomems |
| Musculoskeletal Transplant Foundation INC. | $26.05 | 2022 | |
| Tactile Systems Technology INC | $23.68 | 2022 | |
| Organogenesis INC. | $17.94 | 2022 | |
| Progenacare Global, LLC | $16.92 | 2023 | |
| Cashflow Solutions, LLC | $12.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Mathis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.